Topics:

Bladder Cancer

Bladder Cancer

Presentation with a urinary tract infection delayed a bladder cancer diagnosis among a population of Medicare patients, with worse delays experienced by women.

Phase II study results found that half of patients with relapsed or refractory urothelial carcinoma responded to treatment with pazopanib and paclitaxel.

In this interview we discuss the changing landscape of systemic therapies for the treatment of bladder cancer.

Patients with bladder cancer derived an overall survival benefit from the use of adjuvant chemotherapy compared with observation.

A urine test (CellDetect) was able to detect disease recurrence in bladder cancer patients, with a reported sensitivity of 84.4% and specificity of 82.7%.

While observation may be appropriate for select cases where prognosis is poor, rates of non-treatment are unacceptably high in muscle-invasive bladder cancer.

Long-term survival rates of patients after laparoscopic surgery for bladder cancer are similar to rates achieved with standard open surgery.

Pages

Subscribe to Bladder Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.